AFINITOR

RCC TREATMENT TRACKING

February 2011

CANCE**R** *e* **SEARCH**

2nd LINE METASTATIC RCC TREATMENT

12,090 Patients- MAT February 2011

% 2nd Line metastatic RCC patients

Legend: Feb-10 · May-10 · Aug-10 · Nov-10 · Feb-11 · Next 3 mos.

|	Afinitor	Torisel	Nexavar	Sutent	Votrient	Avastin	Interferon	Proleukin
Feb-10	27.2%	30.8%	24.3%	8.1%	1.9%	5.8%	1.1%	0.6%
May-10	28.8%	25.0%	26.6%	9.7%	4.8%	5.9%	1.5%	1.3%
Aug-10	32.5%	18.5%	22.0%	11.7%	7.2%	7.5%	1.4%	1.1%
Nov-10	35.6%	18.1%	17.1%	11.4%	10.4%	8.4%	1.3%	0.5%
Feb-11	35.4%	18.3%	16.6%	12.7%	10.9%	7.4%	1.1%	1.1%
Next 3 mos.	37.6%	15.6%	15.4%	12.0%	11.1%	8.1%	0.9%	1.0%

Q9. Of your **metastatic** RCC patients that receive **2nd line** drug therapy, how many received each agent below, alone or in combination with other therapy?

Q33. Out of your patients representing the **metastatic** RCC patient base who receive **2nd line** drug therapy, how many are likely to receive the following agents in the next three months?

Cancer e search

3rd LINE METASTATIC RCC TREATMENT

7,227 Patients- MAT February 2011

3rd Line metastatic RCC patients

Legend: ■ Feb-10 ■ May-10 ■ Aug-10 ■ Nov-10 ■ Feb-11

	Afinitor	Avastin	Nexavar	Torisel	Votrient	Sutent	Interferon	Proleukin
Feb-10	23.5%	29.5%	18.2%	16.7%	5.7%	1.3%	1.5%	0.4%
May-10	25.4%	23.8%	15.8%	19.9%	8.9%	4.4%	3.1%	1.3%
Aug-10	24.8%	23.7%	15.3%	18.0%	13.0%	4.3%	3.0%	1.0%
Nov-10	25.8%	21.8%	17.0%	16.2%	13.9%	7.1%	1.3%	0.3%
Feb-11	26.9%	19.2%	17.2%	16.1%	14.4%	6.8%	2.2%	0.9%

Q13. Of your **metastatic** RCC patients that received **3rd line** drug therapy, how many received each agent below, alone or in combination with other therapy?

Cancer e search

# AFINITOR

RCC TREATMENT TRACKING

March 2013

CANCE**R** *e* **SEARCH**

2nd LINE METASTATIC RCC TREATMENT

14,317 Patients- MAT March 2013

% 2nd Line metastatic RCC patients

	Feb-11	May-11	Aug-11	Nov-11	Mar-12	Jun-12	Sep-12	Dec-12	Mar-13	Next 3 mos.
Afinitor	35.4%	35.9%	35.4%	36.2%	35.9%	36.7%	36.2%	34.3%	35.3%	34.9%
Votrient	10.9%	11.5%	10.7%	10.5%	11.2%	11.5%	12.4%	16.6%	14.7%	12.1%
Inlyta					3.7%	7.4%	13.5%	15.8%	18.3%	22.3%
Torisel	18.3%	15.9%	18.8%	18.4%	17.5%	15.2%	12.5%	12.1%	10.6%	8.8%
Sutent	12.7%	13.6%	11.8%	11.1%	10.5%	10.4%	9.3%	10.0%	8.8%	9.6%
Nexavar	16.6%	17.3%	16.9%	17.0%	15.4%	14.2%	10.8%	7.9%	6.9%	5.6%
Avastin	7.4%	6.2%	6.4%	5.9%	5.5%	5.3%	5.5%	4.7%	4.9%	4.6%

Q9. Of your **metastatic** RCC patients that receive **2nd line** drug therapy, how many received each agent below, alone or in combination with other therapy?
Q34. Out of your patients representing the **metastatic** RCC patient base who receive **2nd line** drug therapy, how many are likely to receive the following agents in the next three months?

Cancer e search

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.

fastcase
Smarter legal research.